2026-06-14T03:18:06Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/273432026-03-21T01:17:45Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Estevez, Hector author Garcia-Calvo, Estefania author Álvarez-Fernández Garcia, Roberto author Sanchez-Diaz, Raquel author Lazcano, Juan José author Martin, Pilar author Luque-Garcia, Jose L. author 2025-09 Chitosan-stabilized selenium nanoparticles (Ch-SeNPs) are promising agents for cancer therapy due to their unique physicochemical properties, including spherical morphology and uniform size distribution. This study investigates the molecular mechanisms underlying their antitumoral effects, with a focus on the nuclear proteome. Quantitative proteomic analysis revealed 343 nuclear proteins, 47 of which showed significant changes following Ch-SeNPs treatment. Key regulators such as CDK1 and CDC5 were implicated in cell cycle arrest and tumor suppression pathways. Ch-SeNPs also affected processes including mRNA metabolism and cytoskeleton organization. In addition, Ch-SeNPs significantly inhibited tumor growth in a murine melanoma model, supporting their therapeutic potential. J Drug Deliv Sci Technol. 2023. 10.1016/j.jddst.2025.107155 1773-2247 Journal of Drug Delivery Science and Technology https://hdl.handle.net/20.500.12105/27343 SILAC-based nuclear proteomics uncovers antitumor mechanisms of selenium nanoparticles with in vivo validation in a melanoma model